MedTrace Logo

A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care

NCT02236637 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3050

Last updated 2019-11-12

No results posted yet for this study

Summary

The purpose of this registry is to document the characteristics and management of patients with metastatic castrate resistant prostate cancer (mCRPC) in routine clinical practice, independent of treatment used. Given the rapidly evolving landscape in mCRPC treatments, there is a need for a current and improved understanding of how these treatments fit into the current treatment paradigm for mCRPC, how they are combined and sequenced, and how their relative effectiveness profiles emerge outside of a clinical trial setting. This will be based on documentation and description of sequencing of treatment initiation, termination, and duration; relative effectiveness of treatments; defined medical resource utilization (MRU) and quality-of-life parameters and follow-up for survival.

Conditions

Sponsors & Collaborators

  • Janssen Pharmaceutica N.V., Belgium

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-14
Primary Completion
2018-11-21
Completion
2018-11-21

Countries

  • Austria
  • Belgium
  • France
  • Germany
  • Israel
  • Luxembourg
  • Poland
  • Portugal
  • Russia
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02236637 on ClinicalTrials.gov